Pfizer Share Price Surges After Q4 Profit Jumps, Margin Improves

Share price of Pfizer surged more than 12% to trade at Rs 4,990 and in high volume after its net profit jumped in the fourth quarter of fiscal 2025.

Net profit climbed 85% to Rs 330.94 crore, as compared to Rs 178.86 crore, last year. While, revenue for the period went up 8.3% to Rs 591.91 crore, compared to Rs 546.63 crore in the year ago period.

Earnings before interest, taxes, depreciation, and amortisation rose 20% to Rs 227.50 crore, compared to Rs 189.43 crore in the same period last year.

Margin expanded to 38.4% from 34.7%. The company announced a final dividend of Rs 35 per share.

In February, Pfizer had signed a sales and marketing pact with Mylan Pharmaceuticals Pvt. resulting in upward movement in the share price. The contract was for two brands of the company to conduct marketing and sales of Ativan and Pacitane, two brands owned by Mylan Pharmaceuticals for a period of five years within the territory of India, as per an exchange filing.

Share price of Pfizer rose as much as 11.68% to Rs 4,990 apiece, the highest level since Jan. 20. It pared gains to trade 10.45% higher at Rs 4,934 apiece, as of 10:45 a.m. This compares to a 0.07% decline in the NSE Nifty 50.

The stock has fallen 6.48% on a year-to-date basis, but risen 12.26% in the last 12 months. Total traded volume so far in the day stood at 96 times its 30-day average. Relative strength index was at 71.22.

Out of three analysts tracking the company, two maintain a 'buy' rating and one suggests 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 11.9%.